Pay in 4 interest-free payments of $5.61 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
The Obesity Medicine Association recommends that patients receiving GLP-1 therapy have at minimum a 4-week check-in after initiation, a 3-month metabolic reassessment, and a 6-month weight and adverse-event review
Dosing in the Phase 3 Diabetes Trial (TRANSCEND-T2D-1) A1C reduction: -1.7% to -2.0% across doses (from baseline 7-9.5%) Weight loss at 12 mg: 16.8% (-36.6 lbs) at 40 weeks Discontinuation due to adverse events was relatively low across all doses, similar to the patterns seen in TRIUMPH-4 The diabetes population typically loses less weight on GLP-1 drugs than the obesity-only population, which is consistent with what was observed: ~17% weight loss in T2D vs
However, if generic pricing makes coverage more affordable for employers, there could be an increase in the number of plans that will cover obesity medication
Side effects:What Is the Weight Loss Drug Debate Missing
US$ 22.11
US$ 25.34
US$ 26.80
